Chiesi Group today announced its decision to conclude all clinical trials for the tanimilast program in Chronic Obstructive Pulmonary Disease (COPD) and asthma.

This decision follows the full analysis of the Phase 3 PILASTER Main Cohort study in COPD, which did not meet its primary and key secondary endpoints. No safety concerns were identified.

While this outcome is disappointing, it reflects the complexity of respiratory diseases and the challenges of developing innovative therapies in COPD. The knowledge gained will contribute to future scientific progress and reinforces our commitment to improving the lives of people with chronic respiratory conditions.

Chiesi remains committed to advancing respiratory care through science, innovation, and responsibility—always putting patients and sustainability at the centre.